Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) as well as adult T-cell leukemia-lymphoma (ATLL). In patients with HAM-TSP, HTLV-1 infects mainly CCR4+ T cells and induces functional changes, ultimately causing chronic spinal cord inflammation. We evaluated mogamulizumab, a humanized anti-CCR4 monoclonal antibody that targets infected cells, in patients with HAM-TSP. METHODS: In this uncontrolled, phase 1-2a study, we assessed the safety, pharmacokinetics, and efficacy of mogamulizumab in patients with glucocorticoid-refractory HAM-TSP. In the phase 1 dose-escalation study, 21 patients received a single infusion of mogamulizumab (at doses of 0.003 mg per kilogram of body weight, 0.01 mg per kilogram, 0.03 mg per kilogram, 0.1 mg per kilogram, or 0.3 mg per kilogram) and were observed for 85 days. Of those patients, 19 continued on to the phase 2a study and received infusions, over a period of 24 weeks, of 0.003 mg per kilogram, 0.01 mg per kilogram, or 0.03 mg per kilogram at 8-week intervals or infusions of 0.1 mg per kilogram or 0.3 mg per kilogram at 12-week intervals. RESULTS: The side effects of mogamulizumab did not limit administration up to the maximum dose (0.3 mg per kilogram). The most frequent side effects were grade 1 or 2 rash (in 48% of the patients) and lymphopenia and leukopenia (each in 33%). The dose-dependent reduction in the proviral load in peripheral-blood mononuclear cells (decrease by day 15 of 64.9%; 95% confidence interval [CI], 51.7 to 78.1) and inflammatory markers in cerebrospinal fluid (decrease by day 29 of 37.3% [95% CI, 24.8 to 49.8] in the CXCL10 level and of 21.0% [95% CI, 10.7 to 31.4] in the neopterin level) was maintained with additional infusions throughout the phase 2a study. A reduction in spasticity was noted in 79% of the patients and a decrease in motor disability in 32%. CONCLUSIONS: Mogamulizumab decreased the number of HTLV-1-infected cells and the levels of inflammatory markers. Rash was the chief side effect. The effect of mogamulizumab on clinical HAM-TSP needs to be clarified in future studies. (Funded by the Japan Agency for Medical Research and Development and the Ministry of Health, Labor, and Welfare; UMIN trial number, UMIN000012655 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mogamulizumab targets CCR4, a chemokine receptor highly expressed by HTLV-1-infected T cells [198,199,200], with phase I and II clinical trials resulting in an overall response rate (ORR) of 50% [201,202,203].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
In the citing paper
“A phase I/IIa clinical trial involving 21 patients also reported its utility for HAM [203]. Mogamulizumab reduced HTLV-1 PVL, cytokine production, and spontaneous proliferation, improved motor ability in 32% of patients, and reduced spasticity in 79% of patients.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
In the citing paper
“The most notable side effects were rashes, with the serious adverse events lymphopenia and leukopenia reported in 33% of patients each.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [203]
Citations
Cites
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,424
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & De Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,843
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., & Tara, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91298-5 · Cited by 2,404
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.481 · Cited by 2,316
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence
Avery, K., Donovan, J., Peters, T. J., Shaw, C., Gotoh, M., & Abrams, P. (2004) · Neurourology and Urodynamics · doi:10.1002/nau.20041 · Cited by 1,972
Epidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428
Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score
Homma, Y., Yoshida, M., Seki, N., Yokoyama, O., Kakizaki, H., Gotoh, M., Yamanishi, T., Yamaguchi, O., Takeda, M., & Nishizawa, O. (2006) · Urology · doi:10.1016/j.urology.2006.02.042 · Cited by 764
Research works printed but not linked: 1
- Osame M. Review of WHO Kagoshima Meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA ed. Human retrovirology. New York: Raven Press 1990:191-197.
Cited by
Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Enose-Akahata, Y., & Jacobson, S. (2019) · Retrovirology · doi:10.1186/s12977-019-0499-5 · Cited by 49
Tamaki, K., Sato, T., Tsugawa, J., Fujioka, S., Yagishita, N., Araya, N., Yamauchi, J., Coler-Reilly, A. L. G., Nagasaka, M., Hasegawa, Y., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02110 · Cited by 29
Self-citationCurrent State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
BackgroundSato, T., Nagai, M., Watanabe, O., Misu, T., Takenouchi, N., Ohkubo, R., Ishihara, S., Tsuboi, Y., Katsuno, M., Nakagawa, M., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12239-x · Cited by 21
Self-citation
Metadata
- Authors
- Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., Hasegawa, Y., & Yamano, Y.
- Affiliations
- St. Marianna University School of Medicine (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 529-538
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787149056
- Cited by
- 113
- References
- 33
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 15 · 2023: 10 · 2022: 15 · 2021: 13 · 2020: 19 · 2019: 13 · 2018: 4
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Health Labour and Welfare
- Japan Agency for Medical Research and Development (17ek0109083)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Surgery › Cervical and Thoracic Myelopathy
- Keywords
- mogamulizumab, anti-CCR4 monoclonal antibody, HTLV-1-associated myelopathy/tropical spastic paraparesis, HAM/TSP, adult T-cell leukemia/lymphoma, proviral load, myelitis, neuroinflammation, CXCL10, pharmacokinetics, safety
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Exanthema, Female, Humans, Male, Middle Aged, T-Lymphocytes, Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic, Area Under Curve, Viral Load, Receptors, CCR4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. https://app.cochat.ai/papers/10.1056/nejmoa1704827
- The paper
- Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., Hasegawa, Y., & Yamano, Y. (2018). Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1704827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.